Clinical Trial Imaging Market worth $2.07 billion by 2029

Global clinical trial imaging market valued at $1.32B in 2023, $1.42B in 2024, and set to hit $2.07B by 2029, growing at 7.8% CAGR.
The global clinical trial imaging market, valued at US$1.32 billion in 2023, stood at US$1.42 billion in 2024 and is projected to advance at a resilient CAGR of 7.8% from 2024 to 2029, culminating in a forecasted valuation of US$2.07 billion by the end of the period. Increasing funding in research and development aimed at producing novel disease-fighting medications, coupled with the expansion of biotechnology and pharmaceutical firms, and increasing number of CROs, is expected to drive the market growth. However on the other hand, imaging equipments being slightly overpriced was responsible for growth of imaging services market as well as hindering the growth of the market.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=30446624

Increasing R&D spending in drug discovery/imaging/procedure development, the growth of the biotechnology and pharmaceutical industries, subsequent rise in the number of clinical trials carried out and the rise of Contract Research Organizations (CROs) number willing to carry on R&D are among other contributing reasons for the growth of clinical trial imaging market. Market participants in clinical trial imaging find appealing opportunities in developing nations like China, India, and Japan. The restraining factor in the growth of the market is the implementation cost of the imaging devices. Such hinderance can slow down the market a notch

The services segment accounted for the largest share of the clinical trial imaging market, by service and software segment, in 2023

The clinical trial imaging market is divided into two segments: services and software, based on services and software. Services held the most market share for clinical trial imaging worldwide in 2023. Depending on the therapeutic area, region of interest, and drug candidate properties, various image modalities may be required during clinical evaluation. These comprise CT, MRI, ultrasound, PET, X-ray, and ECHO. The high cost of imaging equipment, which has forced pharmaceutical, biotechnology, and medical device makers to outsource their imaging clinical trials to service providers, is largely to blame for this segment's size

Positron emission tomography segment to register the highest growth rate during the forecast period

Computed tomography, magnetic resonance imaging, ultrasound, positron emission tomography, X-ray, and other modalities are the segments that make up the clinical trial imaging market. By 2023, the segment with the fastest growth rate was positron emission tomography. It is anticipated that advances in technology and the development of novel tracers for use in neurology, cardiology, and oncology will encourage the use of PET systems in clinical trial settings. Also, Factors such as the rising incidence of CVDs, the growing prevalence of lifestyle and age-related disorders, such as hypertension, obesity, dyslipidemia, and diabetes, the increasing availability of cardiac CT devices in major markets, and technological advancements drive segment growth.

The oncology segment accounted for the largest share of the clinical trial imaging market, by therapeutic area segment, in 2023

The therapeutic areas of oncology, infectious diseases, neurology, CVS, endocrinology, immunological disorders, and other therapies are the divisions of the clinical trial imaging market. By 2023, the clinical trial imaging market was dominated by the oncology category. The significant percentage of this segment's market share can be primarily ascribed to the large number of clinical trials connected to oncology, which are being pushed by the rise in cancer incidence worldwide.

North America is the largest regional market for clinical trial imaging market

There are five main regions that make up the global market for clinical trial imaging: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, and the Gulf Cooperation Council. North America held the most market share for clinical trial imaging in 2023. The expanding number of biotechnology and pharmaceutical companies, the growing amount of advanced medical technologies, and the significant government spending in clinical research and development are all responsible for this region's size.

The major players operating in this market are ICON plc. (Ireland), Medpace Holdings, Inc. (US), IXICO plc. (UK), Resonance Health Ltd. (Australia), Radiant Sage LLC. (US), Intrinsic Imaging LLC. (US), Cardiovascular Imaging Technologies LLC. (US), Medical Metrics Inc. (US), Prism Clinical Imaging, Inc. (US), Boston Imaging Core Lab LLC. (US), anagram 4 clinical trials (Spain), Lyscaut Medical Imaging Company (Belgium), Calyx Group (UK), Bioseptive Inc. (Canada), ProScan Imaging LLC. (US), Micron Inc. (Japan), Imaging Endpoints LI, LLC (US), Perspectum Ltd. (UK), Pharmtrace klinische Entwicklung GmbH (Germany), WorldCare Clinical, LLC (US), Median Technologies (France) and Invicro. LLC. (US).

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=30446624

Media Contact
Company Name: MarketsandMarkets Trademark Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=clinical-trial-imaging-market-worth-207-billion-by-2029]
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/clinical-trials-imaging-market-30446624.html

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.